KDM1A and neoplasm: NCD38 (6), a selective LSD1 inactivator optimized from PCPA with IC50 of 0.59 μM (Sugino et al., 2017), could reduce the stemness of TNBC cells and tumor growth in vitro (Zhou et al., 2021a).